Complex laboratory-instrumental and prognostic assessment in hypertensive patients with type 2 diabetes mellitus and atrial fibrillation

Objective. To perform a complex laboratory and instrumental and prognostic assessment of hypertensive subjects with type 2 diabetes mellitus (DM) and atrial fibrillation (AF). Design and methods. Based on the retrospective analysis out of 3150 case records we selected 443 clinical cases of arterial hypertension combined with type 2 diabetes mellitus (DM 2) and with or without atrial fibrillation (AF). They were divided into groups: 1st group included hypertensive patients with DM 2 and AF; 2nd — hypertensives with DM 2, and third — hypertensives with AF. We analyzed haemodynamic, electro-and echocardiography, routine biochemical (blood sugar, glycated hemoglobin, uric acid, potassium, microalbuminuria, cholesterol, low and high density lipoproteins, triglyceride, prothrombin and international normalized ratio, C-reactive protein) parameters, as well as adipokine levels (tumor necrosis factor alpha, adiponectine, leptine, resistine). Kaplan-Meyer’s analysis was performed to assess survival rate. Results. Patients from the 1st group showed subclinical target organ damage, dysregulation of metabolism and hormonal and regulatory activity. Compared to other groups these patients demonstrated a lower survival rate. Conclusion. The association of arterial hypertension, DM 2 and AF can be considered as a mutual burdening phenomenon, increasing the cardiovascular risk.

Download Full-text

Comparative Evaluation of Effect of Valsartan/Amlodipine and Atenolol/Amlodipine Combinations on Atrial Fibrillation Recurrence in Hypertensive Patients With Type 2 Diabetes Mellitus

Journal of Cardiovascular Pharmacology ◽

10.1097/fjc.0b013e318160b42a ◽

2008 ◽

Vol 51 (3) ◽

pp. 217-222 ◽

Cited By ~ 30

Author(s):

Roberto Fogari ◽

Annalisa Zoppi ◽

Amedeo Mugellini ◽

Luca Corradi ◽

Pierangelo Lazzari ◽

...

Keyword(s):

Diabetes Mellitus ◽

Atrial Fibrillation ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Comparative Evaluation ◽

Atrial Fibrillation Recurrence ◽

Hypertensive Patients

Download Full-text

An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity

Obesity and metabolism ◽

10.14341/omet2016349-53 ◽

2016 ◽

Vol 13 (3) ◽

pp. 49-53 ◽

Cited By ~ 2

Author(s):

Liliya Mogylnytska ◽

Boris Mankovsky

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Serum Level ◽

Arterial Hypertension ◽

Serum Insulin ◽

Elevated Serum ◽

Hypertensive Patients ◽

Emap Ii

Objectives: To assess serum levels of endothelial monocyte activating polypeptide-II (EMAP-II) in patients with arterial hypertension with and without type 2 diabetes mellitus and obesity.Materials and methods: We examined 41 hypertensive patients with type 2 diabetes, 18 obese hypertensive patients without diabetes, 9 non-obese hypertensive patients without diabetes, and 18 healthy control subjects.Results: We found an increased serum level of EMAP-II in hypertensive patients with type 2 diabetes compared to controls (4.86±2.3 and 1.08±0.53 ng/ml respectively, р0.01), in hypertensive patients with obesity (2.92±1.42 ng/ml) compared to controls, and in non-obese hypertensive patients (2.02±0.33 ng/ml) compared to controls. Also, the levels of EMAP-II significantly correlated with HbA1c, blood glucose, serum insulin levels, HOMA, lipids, and body mass index (р0.01).Conclusions: The revealed changes could reflect an endothelial dysfunction mostly pronounced in patients with arterial hypertension, type 2 diabetes mellitus and obesity. Hyperglycemia, dyslipidemia, insulin resistance, obesity appear to be significant contributing factors leading to the elevation of EMAP-II.

Download Full-text

The effectiveness of the original form of Iindapamide Retard in hypertensive patients with diabetes mellitus

Arterial’naya Gipertenziya (Arterial Hypertension) ◽

10.18705/1607-419x-2012-18-2-136-141 ◽

2012 ◽

Vol 18 (2) ◽

pp. 136-141

Author(s):

L. I. Tyukalova ◽

N. P. Garganeyeva ◽

M. A. Lukyanova ◽

YU. A. Rakhmatullina

Keyword(s):

Diabetes Mellitus ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Target Blood Pressure ◽

High Density Lipoproteins ◽

Original Form ◽

Hypertensive Patients ◽

Sf 36

Objective. To assess the effectiveness original Indapamide (Arifon Retard, Servier, France) in patients with arterial hypertension and type 2 diabetes mellitus. Design and methods. 30 hypertensive subjects (mean age — 55 ± 4,0 years) with type 2 diabetes mellitus and uncontrolled hypertension, who took any of generic forms of Indapamide. Generic forms were substituted by original drug in all subjects (Arifon Retard). The follow-up lasted for 3 months. We assessed blood pressure changes, achievement of target blood pressure level, the changes of blood pressure according to 24-hout blood pressure monitoring. All subjects also filled in the questionnaires on life quality MOS SF-36 (MOS 36-ltem Short-Form Health Survey). Results. The mean decrease of blood pressure was 29/15 mm Hg. 80 % patients achieved target blood pressure levels. The therapy with original form of Indapamide was safe. We observed the decrease of plasma glucose level, of serum levels of total cholesterol, triglycerides, and low density lipoproteins, while there was a slight increase of the level of high density lipoproteins. According to the survey, the quality of life (MOS SF-36) the indicators of physical and mental health considerably increased. Results. Original Indapamide shows benefits in controlling blood pressure in high risk subjects, in particular, in hypertensive patients with type 2 diabetes mellitus.

Download Full-text